KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

Panelists discuss how recent data from the KEYNOTE-564 trial has changed their approaches to treating patients with renal cell carcinoma by implementing adjuvant pembrolizumab therapy for high-risk patients following nephrectomy, citing improved disease-free survival outcomes.

Now Viewing

EP: 1.KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

EP: 2.Localized Renal Cell Carcinoma: Current Treatment Considerations

EP: 3.IO-TKI Treatment Regimens in the Treatment of mRCC

EP: 4.Recent Trials Guiding mRCC Treatment

EP: 5.Sequencing Therapies for Patients With Renal Cell Carcinoma

EP: 6.Final Insights in Care for Patients With Renal Cell Carcinoma

Recent Videos